|
ACI : Conference-Papers : 2006 : Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements
Structuring, Negotiating and Managing Win/WinPharma and Biotech In-Licensing, Co-Development and Co-Promotion AgreementsMonday, November 14, 2005
AboutAre you sure that your collaboration agreements adequately enhance your client's capabilities without giving away too much?Collaboration among pharmaceutical manufacturers, biotech companies, and research universities has become commonplace, but the issues haven't gotten any less complex. In-licensing, co-development and co-promotion arrangements can offer great benefits in terms of asset exploitation and cost reduction, but they carry great risks as well. These deals are often rife with potential misunderstandings and other minefields. In-house counsel, senior business executives and attorneys must understand all the potential legal and business pitfalls in depth – while also taking into account the latest trends and changes – so they can draft the agreements with full knowledge of the risks, before they are executed. This American Conference Institute publication on Structuring, Negotiating and Managing Win/Win Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the strategies you need to overcome the challenges of creating successful alliances. You'll get the tools you need to negotiate and draft effective agreements that can endure the twists and turns that occur over the long course of product discovery and pipeline development.* The expert faculty of leading pharmaceutical and biotech counsel and executives provide valuable insights on:
*American Conference Institute cannot guarantee that every presentation will be included in the publication. Contents & ContributorsAboutAre you sure that your collaboration agreements adequately enhance your client's capabilities without giving away too much?Collaboration among pharmaceutical manufacturers, biotech companies, and research universities has become commonplace, but the issues haven't gotten any less complex. In-licensing, co-development and co-promotion arrangements can offer great benefits in terms of asset exploitation and cost reduction, but they carry great risks as well. These deals are often rife with potential misunderstandings and other minefields. In-house counsel, senior business executives and attorneys must understand all the potential legal and business pitfalls in depth – while also taking into account the latest trends and changes – so they can draft the agreements with full knowledge of the risks, before they are executed. This American Conference Institute publication on Structuring, Negotiating and Managing Win/Win Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the strategies you need to overcome the challenges of creating successful alliances. You'll get the tools you need to negotiate and draft effective agreements that can endure the twists and turns that occur over the long course of product discovery and pipeline development.* The expert faculty of leading pharmaceutical and biotech counsel and executives provide valuable insights on:
*American Conference Institute cannot guarantee that every presentation will be included in the publication. Contents & ContributorsPHARMA/BIOTECH COLLABORATIONS John W. Gotto, Wyeth Sue Washer, AGTC MOVING FORWARD: THE DRIVES, THE DEALS AND THE LESSONS LEARNED Hemmie Chang, Ropes & Gray DESIGN AND ANALYSIS OF A PATENT PORTFOLIO Ralph A. Loren, Palmer & Dodge BUILD, BUY, LICENSE-IN, CO-DEVELOP? Joel Rothstein Wolfson, Blank Rome LLP STRUCTURING A LICENSE FOR A FUTURE ROYALTY FINANCING Stephen Johnson, Kirkland & Ellis FINDING THE FINANCING & STRUCTURING THE DEAL: THE INTERPLAY OF VENTURE CAPITAL AND LICENSING Jonathan Lourie, Edwards Angell Palmer & Dodge, LLP PAUL ROYALTY FUND OVERVIEW Todd Davis, Paul Capital Partners CHOOSING THE RIGHT PARTNER AND GOVERNANCE STRUCTURE FOR YOUR COLLABORATION Alison J. Freeman-Gleason, Heller Ehrman, LLP CREATING A SUCCESSFUL CO-PROMOTION COLLABORATION Charles E. Yon, Coley Pharmaceutical Group, Inc. CREATING A SUCCESSFUL CO-PROMOTION COLLABORATION: AVOIDING, MINIMIZING AND RESOLVING CONFLICTS Philip M. Hahn, Pfizer Inc. HANDLING FDA RELATED ISSUES IN DRAFTING YOUR COLLABORATION AGREEMENTS Robert A. Dormer, Hyman, Phelps & McNamara, P.C. WORKING FDA RELATED ISSUES INTO YOUR COLLABORATION AGREEMENTS Gregory J. Glover, MD, JD, Ropes & Gray WORKING FDA-RELATED ISSUES INTO YOUR COLLABORATION AGREEMENTS Eric Rogers, Genentech STRUCTURING "WIN-WIN" DEALS WITH UNIVERSITIES Kathleen Denis, Rockefeller University Gregory Ikonen, Arriva Pharmaceuticals Joseph Yanchik, Tokai Pharmaceuticals AVOIDING ANTITRUST PITFALLS IN IN-LICENSING, CO-DEVELOPMENT AND CO-PROMOTION Lore Unt, Federal Trade Commission David Hull, Covington & Burling Stephen A. Stack, Dechert LLP ONE MISSION, MANY COOPERATIVE WAYS: THE CROSS BORDER ASPECTS OF LICENSING, JOINT VENTURES AND OTHER COLLABORATIONS IN THE LIFE SCIENCES Alan Jakimo, Sidley Austin Brown & Wood LLP Mattias Adler, Cooley Godward LLP |
Date: Mon, Nov 14, 2005 Location:
Philadelphia, PA Pricing:
Option 1: Bundle Package
Binder & CD-ROM Save 299 - Best Value! Total: $699 + applicable taxes Option 2: CD-ROM
CD-ROM of program proceedings Total: $499 + applicable taxes Option 3: Binder
Printed copy of program proceedings Total: $499 |
 |
Publication Details |
Copyright 2007 C5 Group Inc. All Rights Reserved. |